These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 23337490

  • 1. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS.
    Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
    [Abstract] [Full Text] [Related]

  • 2. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y, Lee M, Kim HS, Chung HH, Song YS.
    Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
    [Abstract] [Full Text] [Related]

  • 3. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang GN, Liu H, Huang JM, Wang L, Zhao JS, Li C, Mi K, Zhu Y, Cheng J, Zha X.
    Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
    [Abstract] [Full Text] [Related]

  • 4. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, del Carmen MG, Schorge JO.
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [Abstract] [Full Text] [Related]

  • 5. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [Abstract] [Full Text] [Related]

  • 6. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
    Fagö-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, Mosgaard BJ, Ottosen C, Soegaard CH, Soegaard-Andersen E, Hoegdall C.
    Gynecol Oncol; 2014 Feb; 132(2):292-8. PubMed ID: 24321400
    [Abstract] [Full Text] [Related]

  • 7. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A, Mogensen O, dePont Christensen R, Jensen PT.
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [Abstract] [Full Text] [Related]

  • 8. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [Abstract] [Full Text] [Related]

  • 9. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, Bordi G, Vitagliano A, Saccardi C, Skof E.
    Radiol Oncol; 2018 Sep 11; 52(3):307-319. PubMed ID: 30210049
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J.
    Gynecol Oncol; 2016 Jan 11; 140(1):29-35. PubMed ID: 26515076
    [Abstract] [Full Text] [Related]

  • 14. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R.
    Cochrane Database Syst Rev; 2022 Sep 26; 9(9):CD015048. PubMed ID: 36161421
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer.
    Ekmann-Gade AW, Hogdall CK, Engelholm SA, Fago-Olsen CL.
    Anticancer Res; 2020 May 26; 40(5):2765-2770. PubMed ID: 32366422
    [Abstract] [Full Text] [Related]

  • 16. What is the optimal treatment for obese patients with advanced ovarian carcinoma?
    Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, Berkowitz RS, Del Carmen MG, Schorge JO, Horowitz NS.
    Am J Obstet Gynecol; 2014 Sep 26; 211(3):231.e1-9. PubMed ID: 24704062
    [Abstract] [Full Text] [Related]

  • 17. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan 26; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 18. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.
    Nicklin JL, McGrath S, Tripcony L, Garrett A, Land R, Tang A, Perrin L, Chetty N, Jagasia N, Crandon AJ, Nascimento M, Walker G, Sanday K, Obermair A.
    Aust N Z J Obstet Gynaecol; 2017 Dec 26; 57(6):651-658. PubMed ID: 28718942
    [Abstract] [Full Text] [Related]

  • 19. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF, Zhang GN, Peng CR, Shi Y, Shi XW.
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun 25; 56(6):385-392. PubMed ID: 34154313
    [Abstract] [Full Text] [Related]

  • 20. The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery.
    Yang SP, Chen JX, Xu JY, Lei J, Wu SG, Zhou J.
    Cancer Med; 2022 Jul 25; 11(14):2836-2845. PubMed ID: 35274489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.